Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: implications for pre-mRNA processing by Zerbe, L.K. (Laura K.) et al.
Relative Amounts of Antagonistic Splicing
Factors, hnRNP A1 and ASF/SF2, Change
During Neoplastic Lung Growth:
Implications for Pre-mRNA Processing
Laura K. Zerbe,1{ Irene Pino,2{ Ruben Pio,2 Pippa F. Cosper,1 Lori D. Dwyer-Nield,1 Amy M. Meyer,3
J. David Port,3 Luis M. Montuenga,2 and Alvin M. Malkinson1*
1Department of Pharmaceutical Sciences, University of Colorado Health Sciences Center, Denver, Colorado
2Departments of Histology, Pathology, Biochemistry and Center of Applied Medical Research,
University of Navarra, Pamplona, Spain
3Department of Pharmacology, University of Colorado Health Sciences Center, Denver, Colorado
Pre-mRNA processing is an important mechanism for globally modifying cellular protein composition during
tumorigenesis. To understand this process during lung cancer, expression of two key pre-mRNA alternative
splicing factors was compared in a mouse model of early lung carcinogenesis and during regenerative growth
following reversible lung injury. Heterogeneous nuclear ribonucleoprotein (hnRNP) A1 and alternative splicing factor/
splicing factor 2 (ASF/SF2) act antagonistically to modulate splice site selection. Both hnRNP A1 and ASF/SF2 contents
rose in adenomas and during injury-induced hyperplasia compared to control lungs, as measured by immunoblotting.
While both proteins increased similarly during compensatory hyperplasia, hnRNP A1 increased to a much greater
extent than ASF/SF2 in tumors, resulting in a 6-fold increase of the hnRNP A1 to ASF/SF2 ratio. Immunohistochemical
analysis showed that hnRNP A1 localized exclusively within tumor nuclei, while ASF/SF2 appeared in cytoplasm and/or
nuclei, depending on the growth pattern of the tumor cells. We also demonstrated cancer-associated changes in the
pre-mRNA alternative splicing of CD44, a membrane glycoprotein involved in cell-cell and cell-extracellular matrix
interactions. hnRNP A1 and ASF/SF2 expression is thus differentially altered in neoplastic lung cells by mechanisms that
do not strictly arise from increased cell division. These changes are influenced by tumor histology and may be
associated with production of variant CD44 mRNA isoforms.  2004 Wiley-Liss, Inc.
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INTRODUCTION
Lung cancer, the primary cause of cancer deaths in
the US and Europe [1], is seldom diagnosed prior to
metastatic spread. It is, therefore, critical to under-
stand the mechanisms that guide early stages of
tumor development in order to identify biomarkers
and develop improved molecular-targeted chemo-
preventive and chemotherapeutic strategies. There is
growing evidence that modulation of gene expres-
sion at the pre-mRNA level is an important regula-
tory mechanism in tumorigenesis [2]. Pre-mRNA
processing proteins mediate many aspects of prepar-
ing a final mRNA transcript for polysomal transla-
tion, including alternative splicing, stability, and
transport of pre-mRNA [3,4], and thus can influence
the translation into proteins of numerous mRNAs,
including those that facilitate carcinogenesis. Se-
quencing of the human genome has emphasized the
importance of pre-mRNA processing, particularly
alternative splicing, innormal aswell as pathological
tissues. The discovery of far fewer genes than anti-
cipated based on mammalian proteome complexity
indicates that alternative splicing and posttransla-
tional modifications are critical for protein diversity
[5]. In fact, it is estimated that 40–60% of genes are
alternatively spliced into two ormore transcripts [6].
Computational analysis of mRNAs derived from
tumorornormal samples identified845alternatively
spliced isoforms significantly associatedwithhuman
cancer [7].
At least 20 hnRNP proteins in human cells form a
diverse set of large, complexes with heterogeneous
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nuclear RNA during pre-mRNA processing [3].
The pre-mRNA processing protein, heterogeneous
nuclear ribonucleoprotein (hnRNP) A2/B1, has been
proposed as a promising biomarker for lung cancer.
In prospective studies, hnRNP A2/B1 expression in
epithelial cells exfoliated into human sputum pre-
dicted lung cancer in approximately 70% of the
subjects [8]. We demonstrated previously by immu-
nohistochemistry (IHC) that several members of
this family (hnRNP A1, A2, B1, C1, C2, and K) are
increased in tumors compared to normal tissue from
lung cancer patient biopsies [9].We have also shown
that several pre-mRNA processing proteins, hnRNP
A2/B1 [10], hnRNP D, and Hu antigen R (HuR) [11],
increase in mouse lung tumors and related neo-
plastic cell lines, which are preclinical models of
pulmonary adenocarcinoma [12].
Serine/arginine (SR)-rich proteins, another impor-
tant class of pre-mRNA processing proteins involved
in constitutive and alternative splicing, interactwith
the hnRNP proteins. One member of this family,
alternative splicing factor/splicing factor 2 (ASF/
SF2), acts antagonistically to hnRNP A1 to regulate
alternative splicing; increased concentrations of
ASF/SF2 select proximal 50 sites, while high hnRNP
A1 levels promote distal 50 site selection [13,14].
Several SR proteins, including ASF/SF2, increase
during mouse mammary gland tumorigenesis [15].
Because of the increased expression patterns of
hnRNP proteins in human lung cancer and the
known importance of interactions between hnRNP
A1 and ASF/SF2 in regulating alternative splicing, we
evaluated expression of these two proteins in mouse
models of lung AC and lung regenerative repair. Our
results indicate that both hnRNP A1 and ASF/SF2
increase in benign tumors and in nonneoplastic
proliferating lung compared to normal lung tissue.
In tumors, however, hnRNP A1 increased substan-
tially more than ASF/SF2, while both proteins
increased similarly during regenerative hyperplasia.
To demonstrate that alternative splicing indeed
occurs in this lung cancer model, we evaluated the
mRNA isoform pattern of CD44, a gene whose
alternative splicing is associated with many cancers
[16–18]. Interestingly, the increased ratio of hnRNP
A1 relative to ASF/SF2 in tumors corresponded to the
presence of metastasis-associated CD44 splice var-
iants relative to control lung, while no changes




Male BALB/cByJ mice were obtained from Jackson
Laboratories (Bar Harbor, ME) at 5–7 weeks of age,
andallowed toacclimate for10–14daysprior to their
use in experiments. The mice were given access
to Teklad-8640 standard laboratory chow (Harlan
Teklad, Madison, WI) and water ad libitum, and
maintained on a hardwood bedding under a 12 h
light/12 h dark cycle. All injections were given
prior to 10 AM because of circadian effects on BHT
pneumotoxicity (Malkinson, A.M., unpublished
results). Mice were sacrificed by lethal injection of
100 ml 90 mg/ml sodium pentobarbital containing
1000 U/ml heparin (Sigma, St. Louis, MO).
MCA/BHT 2-Stage Lung Carcinogenesis in BALB Mice
Mice were injected IP once with 15mg/kg body wt
MCA (Sigma) dissolved in MazolaTM corn oil (ACH
Food Companies, Memphis, TN), followed by 6
weekly injections of BHT (Sigma; first injection,
150 mg/kg body wt; the second through sixth
injections, 200 mg/kg body wt) dissolved in corn
oil, as described [19]. Mice were sacrificed 26 wks
after MCA injection.
BHT-Induced Acute Lung Injury in BALB Mice
Mice were injected IP once with 200 mg/kg body
wt BHT as described [20], and sacrificed 1 h to 6 days
after BHT administration.
Preparation of Extracts for Immunoblottting
Dissected lungs from untreated or BHT-treated
mice, normal-appearing uninvolved tissue in tumor-
bearing lungs, and tumors were Dounce-homoge-
nized in 100–500 ml solubilization buffer (20 mM
HEPES, pH¼7.5, 2 mM EDTA, 2 mM EGTA, 1 mM
DTT, 10% glycerol, 5 mg/ml aprotinin, and 10 mM
leupeptin), and centrifuged at 16000 g for 25 min
at 48C. After the supernatant (soluble fraction) was
removed, the pellet (particulate fraction) was resus-
pended in solubilization buffer containing 0.1%
NP40, sonicated and an aliquot (10–20 ml) was
removed to determine protein concentration (based
on the method of Lowry et al. [21]). FourX gel-
loading buffer was added to the remaining sample at
a 4-fold dilution (final concentrations: 10% glycerol,
1% SDS, 50 mM Tris, pH¼6.8, 4% b-mercaptoetha-
nol, trace amount of bromophenol blue) and
incubated at 958C for 5 min. All samples were stored
at 708C until immunoblot analysis.
Immunoblotting
Proteins (25–100 mg) were resolved on a 15% SDS-
polyacrylamide gel followed by transfer to an
Immobilon-P membrane (Millipore Corp., Billerica,
MA) and blocked in 3% nonfat dried milk dissolved
in TNS (15 mM Tris, pH¼7.4, 150 mM NaCl) for
30 min. The membranes was then incubated in
primary anti-hnRNP A1 monoclonal antibodies
(4B10 or 9H10, kindly supplied by Dr. G. Dreyfuss,
HHMI,University of Pennsylvania) diluted 1:1000 in
TNS or anti-ASF/SF2 goat polyclonal antibody P-15,
sc-10254 (Santa Cruz Biotechnology, Santa Cruz,
CA) diluted 1:100 in TNS for 1 h and washed in TNS
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with 3% milk and 0.1% Tween 20. For hnRNP A1,
a secondary goat, antimouse antibody (Bio-Rad,
Hercules, CA) was diluted 1:5000 in TNS, while for
ASF/SF2, a rabbit antigoat antibody (A-5420, Sigma)
was diluted 1:25 000 in TNS and incubated for 1 h
followed by washing in TNS with 3%milk and 0.1%
Tween 20. Protein bands were visualized by chemi-
luminiscence after exposure to CL-Xposure film
(Pierce, Rockford, IL) with Immun-StarTM AP sub-
strate (Bio-Rad) for hnRNP A1 andWestern Lighting
(PE Applied Biosystems, Foster, CA) for ASF/SF2.
Immunoreactive proteins on Western blots were
quantified by UN-SCAN-ITTM (Silk Scientific, Orem,
UT). Ponceau-staining (0.1% ponceau in 5% acetic
acid) of proteins transferred to the membrane
confirmed equal protein loading.
Lung Fixation
Immediately after the mice were sacrificed, the
lungs were gently inflated through a canulated
trachea with formalin for 1 h. Lungs were then
removed from the chest cavity and individual lobes
dissected and submerged in formalin overnight.
Fixed lungs were transferred to 95% ethanol and
embedded in paraffin.
Immunohistochemistry
Tissue sections (3 mm) were deparaffinized and
endogenous peroxidase activity blocked by treat-
ment with 3% hydrogen peroxide. For hnRNP A1,
after pretreatment with the Histomouse-SPTM
Blocker Kit (Zymed Laboratories, Inc., San Francisco,
CA), 4B10 primary antibody was used at a 1:1000
dilution overnight at 48C. Slides were rinsed and
incubated with the ENVISIONTM reagent for mouse
monoclonal antibodies (Dakocytomation, Glostrup,
Denmark) for 30 min at room temperature. For ASF/
SF2 immunostaining, slideswere immersed in10mM
citrate buffer, pH 6, and microwaved at two 15-min
cycles to retrieve antigen before blocking with rabbit
normal serum (1:20; Dakocytomation). The sections
were incubated with a primary goat polyclonal
antibody P-10254 (Santa Cruz Biotechnology)
diluted 1:100 at 48C overnight. Addition of an
antigoat rabbit secondary biotinylated antibody
(1:300; Dakocytomation) was followed by ABC
complex incubation (1:100; Dakocytomation).
Immunostaining was developed with diaminoben-
zidine (Dakocytomation) and counter-stained with
hematoxylin.
RT-PCR
Freshly prepared dissected tumor, uninvolved
lung from tumor-bearingmice or control lung tissue
was submerged in 0.5–1 mL ice-cold RNAlater
(Ambion, Austin, TX) and stored at208 until future
analysis. RNA was subsequently isolated with either
TRIzol reagent (Invitrogen, Carlsbad, CA) or RNeasy
mini kit (Qiagen, Valencia, CA). RNA was reverse-
transcribed to DNA with the SuperScriptTM first-
strand synthesis system for RT-PCR (Invitrogen).
CD44 isoforms were amplified with Platinum1 Taq
DNA polymerase (Invitrogen) and primers 50-
ACCCCAGAAGGCTACATTTTGC-30(forward) and
50-CTCATAGGACCAGAAGTTGTGG-30 (reverse) as
previously described [15] at 35 rounds of PCR
consisting of 45 s 948C, 45 s 608C, and 2 min 728C.
PCR products were separated on a 2% agarose gel,
visualized with UV light and quantified by UN-
SCAN-ITTM (Silk Scientific) software.
Statistical Analysis
Data were represented in graphs as mean SEM
and analyzed by Student’s unpaired t-test with Prism
3.0 software (GraphPad, San Diego, CA) In all
analyses, significance was accepted at P< 0.05.
RESULTS
hnRNP A1 and ASF/SF2 Protein Expression
During 2-Stage Carcinogenesis
2-stage carcinogenesis consists of initiation by the
tobacco carcinogen,MCA, followed by promotion of
the growth of initiated cells by BHT. BHT undergoes
extensive pulmonary metabolism in mice to gener-
ate highly reactive oxidative species that cause a
reversible pneumotoxicity consisting of peripheral
epithelial cell damage, regenerative growth, and
inflammation; these properties promote tumor
growth in somemouse strains including BALB when
BHT is administered after a carcinogen [19,20,22–
25]. This experimental model affords the opportu-
nity to compare hnRNP A1 and ASF/SF2 expression
during early neoplasia after 2-stage carcinogenesis
(MCAþBHT) with the nonneoplastic proliferation
that follows BHT treatment alone.
hnRNP A1 and ASF/SF2 protein contents were
measured by immunoblot analysis of dissected
tumors and uninvolved lungs (i.e., normal-appear-
ing tissue adjacent to tumors), isolated from mice
treated with MCAþBHT or whole lungs from age-
matched control mice (Fig. 1). hnRNP A1 levels were
elevated substantially in tumor versus control parti-
culate samples (20 3002260 and 700 230 densi-
tometric values, respectively) resulting in a 30-fold
increase. ASF/SF2 levels also increased in tumor
versus control samples (2100146 and 40049
densitometric values, respectively), but to a lesser
extent than hnRNP A1. This differential increase in
hnRNP A1 compared to ASF/SF2 resulted in nearly a
6-fold elevation of the hnRNP A1 to ASF/SF2 ratio.
Soluble fractions were also analyzed, but negligible
alterations in hnRNP A1 or ASF/SF2 contents were
observed in tumor relative to control lung tissue (0.9-
fold to 1.4-fold increases, data not shown). Both
hnRNP A1 and ASF/SF2 also rose in uninvolved
compared to control tissue (3-fold and 2-fold,
respectively, Fig. 1).
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hnRNP A1 and ASF/SF2 Cellular and Intracellular
Localization During 2-Stage Carcinogenesis
Todetermine thecellular localizationofhnRNPA1
and ASF/SF2, we performed IHC on lung tissue
sections obtained from BALB mice treated with
MCAþBHT (Fig. 2). hnRNP A1 was more highly
expressed in tumor cells than in adjacentuninvolved
alveolar and bronchiolar cells (Fig. 2A), while ASF/
SF2 levels were moderately higher in tumors com-
pared to surrounding pulmonary tissue (Fig. 2B),
similar to immunoblotting experiments (Fig. 1).
Mouse lung adenomas grow in either solid or
papillary patterns; papillary tumors are more aggres-
sive with a greater tendency to progress to malig-
nancy [26]. In both solid and papillary tumors,
hnRNP A1 localized to tumor nuclei (Fig. 2C and
E). In contrast, ASF/SF2 localization varied between
the two pathologies; the solid phenotype contained
both nuclear and cytoplasmic ASF/SF2 (Fig. 2D),
whereas papillary tumors exhibited only cytoplas-
mic localization (Fig. 2F).
hnRNP A1 and ASF/SF2 Expression During
Nonneoplastic Pulmonary Growth Induced by BHT
The contents of hnRNP A1 and ASF/SF2 in tumor
cells may be upregulated consonant with the
increased RNAmetabolism found in rapidly dividing
cells. To examine this, we measured hnRNP A1 and
ASF/SF2 levels during nonneoplastic proliferation.
BHT damage to alveolar type I cells is repaired by a
regenerative growth response of Clara cells and type
2 cells; the latter cell type then differentiates into
type 1 cells to repair the alveolar epithelium [25].
BALB mice were given a single dose of BHT in the
absence of MCA, and lung extracts assessed by
immunoblotting 6 days later in particulate fractions
(Fig. 3). The contents of hnRNP A1 and ASF/SF2 both
Figure 1. Expression of hnRNP A1 and ASF/SF2 protein in mouse
lung tumorigenesis. Immunoblotting of hnRNP A1 (A) and ASF/SF2
(C) was conducted on particulate fractions of age-matched control
lungs (Con), uninvolved lung (UI; normal-appearing tissue in tumor-
bearing lungs) and tumors (Tum) isolated from BALBmice. Mice were
treated with 15 mg/kg body wt MCA, followed by 6 weekly
injections of BHT (first injection, 150 mg/kg body wt; injections 2–
6¼ 200 mg/kg body wt) or 7 corn oil injections and sacrificed after
26 wk. The bands correspond to the expected 34 and 30 kDa
molecular weights of hnRNP A1 and ASF/SF2, respectively. hnRNP A1
(B) and ASF/SF2 (D) immunoreactive protein levels were quantified by
UN-SCAN-IT software. Data represent mean SEM from four mice
per group. For both hnRNP A1 and ASF/SF2, ***P 0.0001 tumor
vs. control samples. Ponceau-staining of proteins transferred to the
membrane confirmed equal protein loading.
Figure 2. Expression and localization of hnRNP A1 and ASF/SF2 in
mouse lung tumorigenesis and in nonneoplastic proliferating lung
cells. Immunohistochemistry (IHC) of hnRNP A1 in solid tumors (A, C),
papillary tumor (E), control lung (G), and BHT-treated lung (I). IHC of
ASF/SF2 in solid tumors (B, D) and papillary tumors (F), control lung
(H), and BHT-treated lung (J). Solid and papillary tumors were derived
from BALB mice treated with 15 mg/kg body wt MCA, followed by 6
weekly injections of BHT (first injection, 150 mg/kg body wt;
injections 2–6¼200 mg/kg body wt) and sacrificed 26 wk after
MCA administration. BHT-treated and control lung samples were
obtained from BALB mice injected with 200 mg/kg body wt BHT or
corn oil, respectively, and sacrificed after 6 days. hnRNP A1 or ASF/
SF2 positive cells are brown. Hematoxylin counterstain. Original
magnification for A, B, C, D, E, and F, 1250 and for G, H, I, and J,
250.
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Figure 2.
rose in BHT-treated lungs relative to control lungs to
a similar extent (5.7-fold and 3.2-fold, respectively).
While significant, these increases were smaller than
that for hnRNP A1 in tumors relative to control lung
(Fig. 1). Similar to neoplastic tissue, hnRNP A1 or
ASF/SF2 expression in soluble fractions of BHT-
treated versus control lung did not change (data
not shown). Because hnRNP A1 and ASF/SF2 each
increased to similar extents during repair of BHT-
induced lung injury, the differential increases of
hnRNP A1 and ASF/SF2 levels in neoplastic lung
tissue probably doesnot simply result from increased
cell division.
hnRNP A1 and ASF/SF2 Localization During
Hyperplasia Induced by BHT
To determine how the cellular localization of
hnRNP A1 and ASF/SF2 in nonneoplastic proliferat-
ing cells compared with their expression in tumors,
IHC was performed on lungs isolated from BHT-
treated BALB mice. We assayed hnRNP A1 and ASF/
SF2 expression between 1 h and 6 days after BHT
exposure. In control mice, hnRNP A1 was not
detectable by IHC in alveolar type 2 or bronchiolar
Clara cells; ASF/SF2 was not detected in type 2 cells
but was expressed in Clara cells (Fig. 2G and H).
Moderate increases in alveolar hnRNP A1 and ASF/SF2
levels occurred early after BHT-treatment; cytoplasmic
ASF/SF2was detected in alveoli within 1 h and nuclear
hnRNP A1 in alveoli by 24 h (data not shown). A few
daysafterBHT-treatment, corresponding to the timeof
maximal cellular proliferation and repair [20,23,25],
high nuclear and cytosolic hnRNPA1were detected in
alveolarandbronchiolar cells (Fig.2I).ASF/SF2content
also reached peak cytosolic and nuclear levels in
alveolar and bronchiolar cells by 6 days, but bronch-
iolar stainingwasmore intense (Fig. 2J). In general, the
intercellular localization of ASF/SF2 was similar in
nonneoplastic proliferating lung tissue and tumors,
displaying both nuclear and cytosolic expression. In
contrast, hnRNP A1 localization differed between the
two pathologies; expression in repairing lungs was
both cytoplasmic and nuclear while tumor expression
was primarily nuclear.
Alternative Splicing of CD44 Pre-mRNA in Lung
Tumors and BHT-Treated Lung—A Candidate
Substrate for hnRNP A1 and ASF/SF2
The relative ratio of hnRNP A1 relative to ASF/SF2
alters the alternative splicing of several pre-mRNAs
Figure 3. Expression of hnRNP A1 and ASF/SF2 protein in
nonneoplastic proliferating lung cells. Immunoblotting of hnRNP
A1 (A) and ASF/SF2 (C) was conducted on particulate fractions of
lung tissue isolated from BALB mice treated with corn oil control
(Con) or 200 mg/kg body wt BHT (BHT). Mice were sacrificed 6 days
after BHT administration. The bands correspond to the expected
34 and 30 kDa molecular weights of hnRNP A1 and ASF/SF2,
respectively. hnRNP A1 (B) and ASF/SF2 (D) immunoreactive protein
levels were quantified by UN-SCAN-IT software. Data represent
mean SEM from five mice per group. For hnRNP A1 **P¼0.0027
and ASF/SF2 ***P< 0.0001 BHT-treated vs. control samples.
Ponceau staining of proteins transferred to the membrane confirmed
equal protein loading.
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in vitro [13,14]. Given the differential increases of
hnRNP A1 and ASF/SF2 in tumors relative to control
tissue reported here, it seemed probable that splicing
of many pre-mRNAs would be affected, including
those involved in tumorigenesis. To begin to test this
hypothesis, the mRNA expression pattern of CD44,
a gene for which alternative splicing has been im-
plicated in many types of cancer including lung
cancer [16,17], was compared in MCA-BHT lung
carcinogenesis, BHT-induced nonneoplastic prolif-
erating lung tissue, and control lung. CD44 is a cell
surface molecule that regulates cell-cell and cell-
extracellular matrix interactions during inflamma-
tion and cancer, and is composed of 20 exons [18].
Particular variants are associatedwithmetastasis; the
CD44standard (CD44s) isoform results from splicing
S1-S5 and S6-S10 exons, while metastasis-associated
CD44variant (CD44v) isoforms include 10 variant
exons in various combinations (Fig. 4A). CD44
isoforms were measured by RT-PCR with primers
that bound S5 and S6 CD44s exons and flanked the
10 CD44 variant exons V1–V10 (Fig. 4A).
In MCAþBHT studies, the mRNA expression
pattern of CD44 switched from predominantly the
single 221 nucleotide long CD44s exon in control
and uninvolved tissues to a series of larger CD44
splice variants in tumors (Fig. 4B), similar to that
observed in other tumor types [15,16,18,27]. In fact,
58% of the total CD44 isoforms were variant in the
lung tumorextracts compared toonly14% incontrol
tissue (Fig. 4D). ThefivemajorCD44variant isoforms
in tumors displayed a ladder pattern indicating
sizes ranging from approximately 492 to 1230 nuc-
leotides long (based on DNA ladder standards) that
Figure 4. Expression pattern of CD44 mRNA isoforms in mouse
lung pathology. The CD44 gene structure showing the 10 variant
exons (V1–V10) flanked by standard exons S5 and S6 (A). RT-PCR
analysis of CD44 mRNA isoforms during 2-stage carcinogenesis (B)
and reparative hyperplasia (C) in BALB mice with primers specific for
standard exons S5 and S6. RNA was isolated from dissected tumors
(Tum), uninvolved lung (UI; normal-appearing tissue in tumor-
bearing lungs), and age-matched control lungs (Con) in tumorigen-
esis studies (B) and from BHT-treated mice (BHT) and age-matched
control lungs (Con) in reparative hyperplasia studies (C). In
tumorigenesis studies mice were treated with 15 mg/kg body wt
MCA, followed by 6 weekly injections of BHT (first injection, 150 mg/
kg body wt; injections 2–6¼ 200 mg/kg body wt) or 7 corn oil
injections and sacrificed after 26 wk and in reparative hyperplasia
studies mice were treated with 200 mg/kg BHT or corn oil and
sacrificed after 6 days. CD44 mRNA isoforms were quantified by UN-
SCAN-IT software. Data represent CD44variant isoforms/CD44total
isoforms 100% and are the mean SEM from 3 to 5 mice per
group (D, E). For tumor versus control ***P0.0001 (D).
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differed in size by approximately 115 nucleotides,
which is comparable to previous reports [15,27]. In
contrast, nonneoplastic proliferating lung in BHT-
treated mice did not exhibit a pattern of CD44
variant isoforms; rather, the CD44s isoform predo-
minated, similar to control lung tissue (Fig. 4C and
E). These data showed that differential increases of
hnRNP A1 and ASF/SF2 in mouse lung tumors
correspond to an altered CD44mRNA splice pattern,
although a causal relationship is not proved.
DISCUSSION
Expression of antagonistic splicing factors, hnRNP
A1 and ASF/SF2, is substantially altered in early
mouse lung neoplasia. The contents of both factors
rose in tumors compared to control lung, but hnRNP
A1 increasedmore thanASF/SF2, resulting in a 6-fold
increase of the hnRNP A1 to ASF/SF2 ratio. Other
groups have shown in vitro that the relative levels of
hnRNP A1 compared to ASF/SF2 affects 50 splice site
selection [13,14], these differential changes in vivo
probably modulate alternative splicing of many
genes, including those involved in carcinogenesis.
The increase in hnRNP A1 and ASF/SF2 is not
exclusively due to the high proliferative activity of
tumor tissues. Both factors rose in regenerating
mouse lung tissue, but did not exhibit an altered
hnRNPA1 toASF/SF2 ratio. This is in agreementwith
our previous results showing that mRNA expression
of several hnRNPs including hnRNP A1 is not
correlated strictly with proliferative index in a panel
of cultured human lung cell lines [9].
The aberrant expression of hnRNP A1 and ASF/SF2
occurred in early-stage tumors of mouse lung
tumorigenesis (26 weeks after MCA injection) that
are typically small with uniform-looking cells.
Adenocarcinomas with increased disorganization
of tumor cells and invasion into the stroma are not
usually observed until 35 weeks after MCA treat-
ment. This early appearance of splice factors
provides evidence that they may regulate initial
stages of neoplastic transformation. In fact, both
ASF/SF2 andhnRNPA1are also significantly elevated
in uninvolved tissue surrounding tumors relative to
control lung, suggesting that they play a role
in the transition of normal cells to neoplastic. If
this is the case, both factors may prove to be
promising biomarkers for lung cancer, similar to
hnRNP A2/B1 [8].
hnRNP A1 localized to the nucleus of tumor cells
while it exhibited both nuclear and cytoplasmic
localization in nonneoplastic proliferating lung
(Fig. 2). ASF/SF2 was observed in both nuclear and
cytoplasmic compartments in tumors as well as
regenerative lung. Theremay be traffickingmechan-
isms that localize hnRNP A1 to the nucleus during
tumorigenesis. Indeed, other investigators have
shown that the phosphorylation status of ASF/SF2
affects its intracellular trafficking between the
nucleus and cytoplasm and determines in part its
nuclear content relative to hnRNP A1 [28,29].
Because pre-mRNA processing proteins elicit glo-
bal changes in mRNA expression, upregulation of
this class of proteins in precancerous lesions can
dramatically affect the neoplastic phenotype. Diver-
sity in the proteome resulting from changes in
alternative splicing would enhance the possibilities
for selecting variant cells capable of overcoming
normal homeostatic controls, and encourage neo-
plastic growth. Protein isoforms spliced from the
same pre-mRNA display unique biological activities
and are subject to distinct regulatory controls. For
example, the short and long isoforms of Bcl-x have
opposing functions in apoptosis [30]. Genes whose
protein isoforms change during tumorigenesis reg-
ulate major hallmarks of neoplasia, including:
oncogenes such as Kras [31] and Wnt [32]; tumor
suppressor genes such as Brca1 [33] and Mdm2 [34];
genes regulating apoptosis such as Bcl2, Fas, and
caspase 2 [35]; genes regulating angiogenesis such as
VEGF [36]; genes involved inDNArepair suchasDNA
polymerase b [37]; genes regulating cell adhesion and
intercellular communication such as CD44 [16]
and cadherin-11 [38]; and genes involved in cellular
senescence such as the INK4a locus (p14ARF and
p16INK4a) [39].
The best-characterized example of how hnRNP A1
and ASF/SF2 may modulate mRNA alternative spli-
cing is CD44, a membrane glycoprotein that binds
hyaluronic acid and osteopontin and is involved in
cell-cell and cell-extracellular matrix interactions
[16,18]. CD44 has multiple alternative splice forms,
with particular variants associated with metastasis.
These variant species influence primary tumor
growth and enable tumor cells circulating in the
vasculature to adhere to the vascular endothelium,
thereby facilitating tumor seeding at distant sites. In
vitro studies show that hnRNP A1 binds regulatory
splice elements in CD44 variant exon v5 and modu-
lates its cancer-associated alternative splicing [40].
Changes in the concentrations of ASF/SF2 corre-
spond to altered CD44 splicing in mouse mammary
gland tumorigenesis [15] and human colon adeno-
carcinoma [27]. We describe herein a substantial
increase in the metastatic-associated CD44 mRNA
isoforms in lung tumors compared to regenerative
proliferating lung, uninvolved lung, and control
tissue. The parallel time course of increased hnRNP
A1 and ASF/SF2 expression with appearance of the
variant CD44 isoforms suggests that hnRNP A1 and
ASF/SF2 may be involved in these splicing changes.
There are numerous additional splicing factors,
however, and changes in one or several of these
may also impact expression of variant CD44 iso-
forms. We are currently conducting in vitro studies
to delineate any causal role between aberrant hnRNP
A1 and ASF/SF2 expression and alternative splicing
of CD44 as well as other cancer-associated genes.
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In summary, numerous enhancing and repressing
proteins interact ina combinatorial fashionwithpre-
mRNA and the spliceosome to direct splice-site
selection [3,4]. Because of this complexity, very little
is known about this process in awhole animalmodel
or how it becomes dysregulated during disease states
including cancer. The intriguing changes in hnRNP
A1 and ASF/SF2 in mouse lung tumors described
herein are the beginnings of an effort to characterize
the role of pre-mRNA alternative splicing in lung
neoplasia. This unique neoplastic expression profile
of splicing factors could serve as a diagnostic tool for
identifying early lung cancer as well as distinguish-
ing lung cancer subtypes.
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